Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Upcoming Events
May 7, 2025
Q1 2025 Financial Results
June 25, 2025
Annual General Meeting
Jefferies 2024 Global Healthcare Conference
Valneva presented at the Jefferies London Healthcare Conference.
Access the webcast of a fireside chat with our CEO here.
Contact
Investor Relations Team
Campus Bio-Ouest6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva.com